Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell genotyping of Myeloid Leukaemia of Down Syndrome cells

ABSTRACT: Single cell genotyping of Myeloid Leukaemia of Down Syndrome cells

PROVIDER: PRJEB32618 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3326710_1.fastq.gz	Fastqsanger.gz
	ERR3326710_2.fastq.gz	Fastqsanger.gz
	ERR3326720_1.fastq.gz	Fastqsanger.gz
	ERR3326720_2.fastq.gz	Fastqsanger.gz
	ERR3326730_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 470

Similar Datasets

RNA sequencing data from Myeloid Leukaemia of Down Syndrome (ML-DS)

Project description:RNA sequencing data from Myeloid Leukaemia of Down Syndrome (ML-DS)

| PRJEB32403 | ENA

Down Syndrome

Project description:Down Syndrome

| PRJNA804910 | ENA

Transcriptomic profiling of 2 cell lines from Down-Syndrome children with Acute Lymphoblastic Leukaemia (DS-ALL)

Project description:Two cell lines derived from 2 Down Syndrome children who developed Acute Lymphoblastic Leukaemia were profiled at the transcriptomic level (bulk RNAseq) and compared against their Patient-Derived Xenograft (PDX) of origin.

2024-07-10 | GSE245056 | GEO

Down syndrome SNPs - samples

Project description:Down syndrome SNP genotyping data

| EGAD00010000464 | EGA

Down syndrome CNVs - samples

Project description:Down syndrome CNV genotyping data

| EGAD00010000466 | EGA

Phosphoproteomic profiling of Acute Myeloid Leukaemia

Project description:Acute Myeloid Leukaemia (AML) carries a 5 year survival rate of just 24%. Toxic chemotherapy regimens remain the backbone of standard of care for AML. The FLT3 tyrosine kinase is a recognised AML oncogene, with FLT3 activating mutations occurring in approximately one third of all AML patients. However, therapeutic targeting of FLT3 has proven difficult as monotherapy, with the development of drug resistance and relapse. Characterisation of the signalling pathways regulated by mutant FLT3 is required to identify better therapeutic strategies.

2019-12-20 | MSV000084730 | MassIVE

Transcription profiling of humans to investigate between transient vs acute megakaryoblastic leukaemia (TMD vs AMKL) in Downs syndrome

Project description:Comparison of transient myeloproliferative disorder and acute megakaryoblastic leukaemia in Down syndrome.

2004-09-01 | E-MEXP-72 | biostudies-arrayexpress

Single cell genotyping of Myeloid Leukaemia of Down Syndrome cells

Project description:Single cells from ML-DS sample 186-2 (bone marrow) were analysed to determine whether mutations in JAK2 and CSF2RB ocurred in the same or different cells in this patient. Single live, CD19neg, CD3neg, CD45mid and CD117 positive cells were sorted into 96-well plates on the BD Fusion with antibodies as described above. Cord blood single cells were sorted similarly to serve as a control for the single cell Sequencing.

2020-12-31 | E-MTAB-7935 | biostudies-arrayexpress

Landscape of gene mutations in Down syndrome-related myeloid disorders

Project description:To identify the spectrum of gene mutations in Down syndrome-related myeloid disorders, whole genome sequencing of 4 trio samples from TAM/AMKL/complete remission (CR) phases and whole exome sequencing of 15 TAM and 14 DS-AMKL samples were performed.

| EGAS00001000546 | EGA

RNA sequestration in P-bodies sustains myeloid leukaemia

Project description:Post-transcriptional mechanisms are fundamental safeguards of progenitor cell identity and are often dysregulated in cancer. Here, we identified regulators of P-bodies as crucial vulnerabilities in acute myeloid leukaemia (AML) through genome-wide CRISPR screens in normal and malignant haematopoietic progenitors. We found that leukaemia cells harbour aberrantly elevated numbers of P-bodies and show that P-body assembly is crucial for initiation and maintenance of AML. Notably, P-body loss had little effect upon homoeostatic haematopoiesis but impacted regenerative haematopoiesis. Molecular characterization of P-bodies purified from human AML cells unveiled their critical role in sequestering messenger RNAs encoding potent tumour suppressors from the translational machinery. P-body dissolution promoted translation of these mRNAs, which in turn rewired gene expression and chromatin architecture in leukaemia cells. Collectively, our findings highlight the contrasting and unique roles of RNA sequestration in P-bodies during tissue homoeostasis and oncogenesis. These insights open potential avenues for understanding myeloid leukaemia and potential therapeutic interventions.

2024-08-08 | GSE224643 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data